Effect of voxelotor on neutrophil counts, markers of endothelial activation, and coagulation
| . | Matched controls (n = 19) . | Patients with SCD (n = 15) . | P value∗ . | |
|---|---|---|---|---|
| Baseline . | Follow-up at 3 mo . | |||
| Neutrophils, 109/L | 2.9 (2.6-4.8) | 4.6 (3.5-5.7)† | 3.5 (2.5-5.0) | .057 |
| VWF-Ag, % | 112 (77-143) | 270 (214-257)† | 178 (140-219) | .005 |
| F1+2, pmol/L | 130 (104-209) | 365 (238-590)† | 279 (210-360) | .510 |
| D-dimer, mg/L FEU | 0.33 (0.21-0.55) | 2.4 (1.1-3.8)† | 1.5 (0.8-4.4) | .683 |
| sVCAM-1, pg/mL | N.A. | 1179 (887-1650) | 975 (662-1510) | .221 |
| TAT, μg/L | N.A. | 5.2 (3.6-8.3) | 4.3 (3.0-6.4) | .638 |
| . | Matched controls (n = 19) . | Patients with SCD (n = 15) . | P value∗ . | |
|---|---|---|---|---|
| Baseline . | Follow-up at 3 mo . | |||
| Neutrophils, 109/L | 2.9 (2.6-4.8) | 4.6 (3.5-5.7)† | 3.5 (2.5-5.0) | .057 |
| VWF-Ag, % | 112 (77-143) | 270 (214-257)† | 178 (140-219) | .005 |
| F1+2, pmol/L | 130 (104-209) | 365 (238-590)† | 279 (210-360) | .510 |
| D-dimer, mg/L FEU | 0.33 (0.21-0.55) | 2.4 (1.1-3.8)† | 1.5 (0.8-4.4) | .683 |
| sVCAM-1, pg/mL | N.A. | 1179 (887-1650) | 975 (662-1510) | .221 |
| TAT, μg/L | N.A. | 5.2 (3.6-8.3) | 4.3 (3.0-6.4) | .638 |
FEU, fibrinogen equivalent units; N.A., not available; sVCAM-1, soluble vascular cell adhesion molecule 1; TAT, thrombin-antithrombin complexes.
Data are medians, with interquartile ranges in parentheses.
P value for difference between baseline and 3-months follow-up within the treated patients.
Significantly different (P < .001) compared with ethnicity-matched healthy controls.